Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan;198(1):89-92.
doi: 10.1007/s00066-021-01882-2. Epub 2021 Nov 25.

[Influence of adjuvant vs early salvage radiotherapy on lethality in men with high risk for recurrence following radical prostatectomy for prostate cancer]

[Article in German]
Simon K B Spohn  1 , Anca-Ligia Grosu  2
Affiliations
Comment

[Influence of adjuvant vs early salvage radiotherapy on lethality in men with high risk for recurrence following radical prostatectomy for prostate cancer]

[Article in German]
Simon K B Spohn et al. Strahlenther Onkol. 2022 Jan.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1341–1352. doi: 10.1016/S1470-2045(20)30454-X. - DOI - PubMed
    1. Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;396(10260):1413–1421. doi: 10.1016/S0140-6736(20)31553-1. - DOI - PMC - PubMed
    1. Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020;21(10):1331–1340. doi: 10.1016/S1470-2045(20)30456-3. - DOI - PubMed
    1. Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020;396(10260):1422–1431. doi: 10.1016/S0140-6736(20)31952-8. - DOI - PMC - PubMed
    1. Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, Bruycker AD, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial. J Clin Oncol. 2020;38(6_suppl):10. doi: 10.1200/JCO.2020.38.6_suppl.10. - DOI